A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

August 14, 2017

Study Completion Date

August 14, 2017

Conditions
Asthma
Interventions
DRUG

Fluticasone/Formoterol BAI

DRUG

Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)

Trial Locations (16)

1051

The New Zealand Respiratory and Sleep Institute, Greenlane

3004

Allergy immunology and Respiratory medicine, The Alfred Hospital, Melbourne

3128

Epworth Eastern Medical Centre, Box Hill

9016

Otago Respiratory Research Unit, Dunedin

NSW 2037

The Woolcock Institute of Medical Research, Glebe

066 01

INSPIRO, s.r.o. Ambulancia pneumológie a ftizeológie, Humenné

029 01

DAMIZA, s.r.o. Ambulancia pneumológie a ftizeológie, Námestovo

05801

Poliklinika ADUS, Pľúcna ambulancia, Poprad

080 01

PULMO, s.r.o, Prešov

052 01

Pľúcna ambulancia Hrebenár, s.r.o., Spišská Nová Ves

955 01

ANA JJ, s.r.o, Ambulancia klinickej imunológie a alergológie, Topoľčany

221 85

Skane University Hospital, Lund

LE3 9QP

Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester

BD9 6RJ

Bradford Teaching Hospital, Bradford

SW3 6HP

Royal Brompton and Harefield Foundation Trust, London

M23 9QZ

University Hospital of South Manchester, Manchester

All Listed Sponsors
lead

Mundipharma Research Limited

INDUSTRY

NCT02753712 - A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma | Biotech Hunter | Biotech Hunter